BioLineRx Ltd. (NASDAQ:BLRX)‘s stock had its “buy” rating reissued by Roth Capital in a research report issued to clients and investors on Monday. They presently have a $7.00 target price on the stock.

A number of other research analysts have also recently issued reports on BLRX. Zacks Investment Research cut shares of BioLineRx from a “hold” rating to a “sell” rating in a report on Thursday, November 24th. Maxim Group set a $1.00 price objective on shares of BioLineRx and gave the stock a “hold” rating in a research note on Tuesday, November 22nd. Finally, S&P Equity Research dropped their price objective on shares of BioLineRx from $1.24 to $1.10 in a research note on Friday, September 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. BioLineRx has an average rating of “Hold” and a consensus target price of $2.68.

Shares of BioLineRx (NASDAQ:BLRX) opened at 1.01 on Monday. The firm has a 50-day moving average price of $0.00 and a 200-day moving average price of $0.00. The stock’s market cap is $57.00 million. BioLineRx has a 12 month low of $0.71 and a 12 month high of $1.63.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Tuesday, November 22nd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by $0.01. Equities analysts expect that BioLineRx will post ($0.28) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this story can be accessed at

A number of hedge funds have recently made changes to their positions in the company. KCG Holdings Inc. raised its stake in shares of BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock worth $174,000 after buying an additional 121,650 shares during the period. Morgan Stanley raised its stake in shares of BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock worth $634,000 after buying an additional 66,900 shares during the period. Finally, Senvest Management LLC raised its stake in shares of BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock worth $5,110,000 after buying an additional 900,200 shares during the period. Hedge funds and other institutional investors own 13.53% of the company’s stock.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

5 Day Chart for NASDAQ:BLRX

Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.